• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Making decisions about antithrombotic therapy in heart disease: decision analytic and cost-effectiveness issues.

作者信息

Eckman M H, Levine H J, Salem D N, Pauker S G

机构信息

Division of General Medicine, New England Medical Center, Boston, MA 02111, USA.

出版信息

Chest. 1998 Nov;114(5 Suppl):699S-714S. doi: 10.1378/chest.114.5_supplement.699s.

DOI:10.1378/chest.114.5_supplement.699s
PMID:9822072
Abstract
摘要

相似文献

1
Making decisions about antithrombotic therapy in heart disease: decision analytic and cost-effectiveness issues.
Chest. 1998 Nov;114(5 Suppl):699S-714S. doi: 10.1378/chest.114.5_supplement.699s.
2
Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data.心房颤动中的中风与血栓栓塞：中风危险因素、风险分层方案及成本效益数据的系统评价
Thromb Haemost. 2008 Feb;99(2):295-304. doi: 10.1160/TH07-08-0508.
3
Dabigatran compared with warfarin for stroke prevention in atrial fibrillation.达比加群与华法林在心房颤动卒中预防中的比较。
Ann Intern Med. 2011 Apr 19;154(8):570; author reply 570-1. doi: 10.7326/0003-4819-154-8-201104190-00013.
4
Barriers to the use of warfarin: potential solutions.华法林使用的障碍：潜在解决方案。
J Interv Card Electrophysiol. 2004;10 Suppl 1:17-20. doi: 10.1023/B:JICE.0000011341.67214.2e.
5
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.达比加群酯与华法林预防房颤卒中的成本效果比较。
Ann Intern Med. 2011 Jan 4;154(1):1-11. doi: 10.7326/0003-4819-154-1-201101040-00289. Epub 2010 Nov 1.
6
[Atrial fibrillation: new anticoagulants are more effective and safer, but expensive].
Praxis (Bern 1994). 2014 Jun 18;103(13):785-6. doi: 10.1024/1661-8157/a001681.
7
[Antithrombotic treatment in atrial fibrillation. Background to new recommendations and therapeutic alternative].[心房颤动的抗栓治疗。新推荐及治疗选择的背景]
Lakartidningen. 2008;105(37):2478-80.
8
[Guidelines for antithrombotic therapy in atrial fibrillation: what the Italian Hemostasis and Thrombosis Society thinks].[心房颤动抗栓治疗指南：意大利止血与血栓形成学会的观点]
Haematologica. 2001 Sep;86(9 Suppl):12-3.
9
Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation.华法林与阿司匹林预防非瓣膜性心房颤动患者卒中的成本效益分析
JAMA. 1995 Dec 20;274(23):1839-45.
10
Dabigatran compared with warfarin for stroke prevention in atrial fibrillation.达比加群与华法林用于心房颤动卒中预防的比较。
Ann Intern Med. 2011 Apr 19;154(8):570; author reply 570-1. doi: 10.7326/0003-4819-154-8-201104190-00012.

引用本文的文献

1
Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.接受冠状动脉介入治疗后接受双联抗血小板治疗和三联治疗的患者的出血风险：ADAPTT 回顾性基于人群的队列研究。
Health Technol Assess. 2023 May;27(8):1-257. doi: 10.3310/MNJY9014.
2
Systematic review of interventions to improve safety and quality of anticoagulant prescribing for therapeutic indications for hospital inpatients.系统评价干预措施以改善医院住院患者治疗性适应证的抗凝药物处方的安全性和质量。
Eur J Clin Pharmacol. 2019 Dec;75(12):1645-1657. doi: 10.1007/s00228-019-02752-8. Epub 2019 Sep 11.
3
Preferences for oral anticoagulants in atrial fibrillation: a best-best discrete choice experiment.
心房颤动患者口服抗凝剂的偏好：最佳-最佳离散选择实验
Pharmacoeconomics. 2014 Nov;32(11):1115-27. doi: 10.1007/s40273-014-0188-0.
4
Cost effectiveness of treatments for stroke prevention in atrial fibrillation: focus on the novel oral anticoagulants.房颤卒中预防治疗的成本效益：关注新型口服抗凝药物。
Pharmacoeconomics. 2013 Nov;31(11):971-80. doi: 10.1007/s40273-013-0090-1.
5
Combined survival analysis of cardiac patients by a Cox PH model and a Markov chain.通过Cox比例风险模型和马尔可夫链对心脏病患者进行联合生存分析。
Lifetime Data Anal. 2011 Oct;17(4):496-513. doi: 10.1007/s10985-011-9196-y. Epub 2011 Jul 7.
6
Cost effectiveness of fondaparinux in non-ST-elevation acute coronary syndrome.磺达肝癸钠在非ST段抬高型急性冠状动脉综合征中的成本效益
Pharmacoeconomics. 2009;27(7):585-95. doi: 10.2165/11310120-000000000-00000.
7
Values and preferences in oral anticoagulation in patients with atrial fibrillation, physicians' and patients' perspectives: protocol for a two-phase study.心房颤动患者口服抗凝治疗中的价值观和偏好：医生与患者视角的两阶段研究方案
BMC Health Serv Res. 2008 Oct 27;8:221. doi: 10.1186/1472-6963-8-221.
8
Application of a decision support tool for anticoagulation in patients with non-valvular atrial fibrillation.一种用于非瓣膜性心房颤动患者抗凝治疗的决策支持工具的应用。
J Gen Intern Med. 2008 Apr;23(4):411-7. doi: 10.1007/s11606-007-0477-9.
9
Modelling methods for pharmacoeconomics and health technology assessment: an overview and guide.药物经济学与卫生技术评估的建模方法：概述与指南
Pharmacoeconomics. 2008;26(2):131-48. doi: 10.2165/00019053-200826020-00004.
10
Multifaceted implementation of stroke prevention guidelines in primary care: cluster-randomised evaluation of clinical and cost effectiveness.初级保健中卒中预防指南的多方面实施：临床和成本效益的整群随机评估
Qual Saf Health Care. 2007 Feb;16(1):51-9. doi: 10.1136/qshc.2006.019778.